The overall trend for Genta Incorporated (OTC:GNTA) is still negative. Yet, the company shares continue to be traded vigorously. There are different sets of traders, however, and they don`t exactly share the same sentiment, let alone percentage of gains. 
One iHub poster even puts it this way – “gnta is a super nice ATM for insiders“. There is a graphic associated with the post, but maybe the insider transactions provide an even better idea in support of what he meant.
Opinions aside, there are facts, which no one can argue with, one of which is the truly horrifying crash of the stock in a matter of just three months. On Dec. 23rd, 2010 the shares were traded at levels around $1.7 per share; on March 24th, 2011 the price revolves around $0.03 and there is no objective reason to justify eventual reversal of this negative trend.
There are, however, results, which if achieved in the near future could not only reverse the trend, but also cause the stock price to accumulate value faster than it has lost it in the last three months. Genta Incorporated is a company focused on developing drugs for treatment of different forms of cancer. Products of the company are in phase 1, 2 or 3 trials, so it is ultimately all up to their results.
Mainly, hopes are associated with Genasense, a product of the company, which has already passed phase 2 trials. Yet, its current status is not what traders are hoping for according to the database of the U.S. National Institutes of Health.
In terms, until Genasense and the other products of the company make it to the marketplace, even if the negative trend on the market transcends into stability close to sub-penny levels, uncertainty would remain as strong as today. The goals of the company are truly ambitious, yet until they are achieved it is unlikely that investors, especially the ones who bought their shares in previous months, would justify their losses up-to-date with the nobility of Genta`s cause.
